A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE

简要总结

主要结局

次要结局

• Percentage of participants to achieve a clinically meaningful improvement in DAS28-ESR (reduction of at least 1.2 units)(Up to Week 24)
• Time to achieve a clinically meaningful improvement in DAS28-ESR (reduction of at least 1.2 units)(Up to Week 24)
• Time to achieve a major and minor improvement in CDAl (>=13.9 and >=6.7, respectively) and SDAI (>=17.1 and >=6.9, respectively)(Up to Week 24)
• Percentage of participants to achieve low disease activity (LDA) using DAS28 (less than or equal to [<=] 3.2), CDAl (<=10.0) and SDAI (<=11 .0)(Up to Week 24)
• Change from baseline in total tender joint count (TJC)(Up to Week 24)
• Physician Global Assessment of disease activity VAS score(Up to Week 24)
• Percentage of participants to achieve disease remission using DAS28-ESR (<2.6), CDAl (<=2.8) and SDAI (<=3.3)(Up to Week 24)
• Time to achieve low disease activity (LDA) using DAS28 (<= 3.2), CDAl (<=10.0) and SDAI (<=11 .0)(Up to week 24)
• Time to achieve disease remission using DAS28-ESR (<2.6), CDAl (<=2.8) and SDAI (<=3.3)(Up to Week 24)
• Correlation Coefficient Between CDAI and simplified disease activity index (SDAI) and Between SDAI and DAS28-ESR(Up to Week 24)
• Change from baseline in total swollen joint count (SJC)(Up to Week 24)
• Percentage of participants having TJC <=1(Up to Week 24)
• Patient Global Assessment of disease activity visual analogue scale (VAS) score(Up to Week 24)
• Percentage of participants having CRP <=1mg/dl(Up to Week 24)
• Health Assessment Questionnaire Disability Index (HAQ-DI)(Up to Week 24)
• EQ-5D-5L Health Questionnaire (EuroQoL)(Up to Week 24)
• Morisky Medication-Taking Adherence Scale (MMAS)(Up to Week 24)
• Percentage of participants using TCZ in monotherapy(At baseline)
• Percentage of participants presenting a high inflammation (DAS28-ESR >5.1)(At baseline)
• Percentage of participants to achieve a major and minor improvement in CDAl (more than or equal to [>=]13.9 and >=6.7, respectively) and SDAI (>=17.1 and >=6.9, respectively)(Up to Week 24)
• Percentage of participants having SJC <=1(Up to Week 24)
• Percentage of participants using TCZ in combination with disease-modifying antirheumatic drug's (DMARD's)(At baseline)